Compare · OBIO vs RLX
OBIO vs RLX
Side-by-side comparison of Orchestra BioMed Holdings Inc. (OBIO) and RLX Technology Inc. (RLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OBIO and RLX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RLX is the larger of the two at $3.07B, about 12.7x OBIO ($241.3M).
- Over the past year, OBIO is up 20.5% and RLX is down 9.3% - OBIO leads by 29.8 points.
- OBIO has been more active in the news (11 items in the past 4 weeks vs 2 for RLX).
- OBIO has more recent analyst coverage (9 ratings vs 2 for RLX).
PerformanceOBIO+20.48%RLX-9.34%
2025-06-10+0.00%2026-06-09
- Company
- Orchestra BioMed Holdings Inc.
- RLX Technology Inc.
- Price
- $4.03+2.03%
- $1.99+0.51%
- Market cap
- $241.3M
- $3.07B
- 1M return
- -0.25%
- -5.91%
- 1Y return
- +20.48%
- -9.34%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- 2021
- News (4w)
- 11
- 2
- Recent ratings
- 9
- 2
RLX
RLX Technology Inc.
RLX Technology Inc., together with its subsidiaries, researchers, develops, manufactures, distributes, and sells e-vapor products in the People's Republic of China. It serves RELX branded partner stores and other retail outlets through distributors. RLX Technology Inc. was founded in 2018 and is based in Beijing, China.
Latest OBIO
- Officer Hochman David P bought $19,150 worth of shares (5,000 units at $3.83), increasing direct ownership by 0.47% to 1,064,029 units (SEC Form 4)
- Officer Sherman Darren sold $58,050 worth of shares (15,000 units at $3.87) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,184,327 units (SEC Form 4)
- Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 144 filed by Orchestra BioMed Holdings Inc.
- Chief Financial Officer Taylor Andrew Lawrence covered exercise/tax liability with 3,076 shares, decreasing direct ownership by 0.49% to 629,417 units (SEC Form 4) (for tax liability)
- Officer Sherman Darren covered exercise/tax liability with 4,925 shares, decreasing direct ownership by 0.41% to 1,199,327 units (SEC Form 4) to satisfy tax liability
- Director Aryeh Jason bought $2,494 worth of shares (665 units at $3.75), increasing direct ownership by 0.57% to 118,118 units (SEC Form 4)
- Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference
- Officer Hochman David P bought $18,850 worth of shares (5,000 units at $3.77), increasing direct ownership by 0.47% to 1,059,029 units (SEC Form 4)
- Director Aryeh Jason bought $34,987 worth of shares (8,971 units at $3.90), increasing direct ownership by 8% to 117,453 units (SEC Form 4)
Latest RLX
- SEC Form 6-K filed by RLX Technology Inc.
- RLX Technology Announces Unaudited First Quarter 2026 Financial Results
- RLX Technology to Report First Quarter 2026 Financial Results on May 20, 2026
- RLX Technology Files 2025 Annual Report on Form 20-F
- SEC Form 20-F filed by RLX Technology Inc.
- SEC Form 3 filed by new insider Wang Ying Kate
- SEC Form 3 filed by new insider Jiang Long
- SEC Form 3 filed by new insider Xi Youmin
- SEC Form 3 filed by new insider Wen Yilong
- SEC Form 3 filed by new insider Lu Chao